{
    "title": "112_hr6502",
    "content": "The Act titled \"Life-Threatening Diseases Compassion through Combination Therapy Act of 2012\" promotes the development of combinations of investigational new drugs for serious diseases by providing marketing exclusivity and priority review for significant drug combinations. The Secretary may designate a combination of drugs as significant if it includes 2 or more drugs offering potential advancement in treating serious diseases, meeting criteria for codevelopment as specified by the FDA. The Secretary may designate a combination of drugs as significant if it includes at least 2 unapproved drugs for codevelopment to encourage the development of such drug combinations based on task force recommendations. The codevelopment task force can submit recommendations under the Life-Threatening Diseases Compassion through Combination Therapy Act of 2012. Manufacturers can request the Secretary to determine if a combination of drugs is significant, with a response required within 30 days. If the combination meets the requirements, it will be designated as a significant drug combination. If a combination of drugs meets the requirements for designation as a significant drug combination, the Secretary will provide notice to the submitter. The Secretary will provide notice to the submitter if a drug combination meets the requirements for designation as significant. Requests for designation must be made concurrently with or after submitting an application for drug investigation, but before completion of phase I trials for any of the drugs involved. The Secretary will develop and publish a list of significant drug combinations within 180 days of the enactment of the Life-Threatening Diseases Compassion through Combination Therapy Act of 2012. This list will be updated annually to include new significant drug combinations and exclude others. The Secretary will annually update the list of significant drug combinations to include new ones and exclude those that no longer meet the criteria. This update extends market exclusivity for drugs included in designated significant combinations. The extension of market exclusivity for drugs in designated significant combinations is subject to certain limitations, such as not applying to supplements for drugs with existing extensions or subsequent applications from the same sponsor or manufacturer. The extension of market exclusivity for drugs in designated significant combinations is limited to certain conditions, excluding supplements for drugs with existing extensions or subsequent applications from the same sponsor or manufacturer. If a drug in a significant combination is designated, the Secretary will prioritize the review and action on any application submitted for such drug. The Secretary will prioritize the review and action on any application for a drug in a significant combination, ensuring a timely response within 6 months. The definition of significantly advancing treatment includes providing treatment for life-threatening conditions with no existing therapy or improving outcomes compared to alternative therapies. The drug combination must demonstrate improved effects on serious outcomes of a disease compared to alternative therapies, such as superiority or minimizing drug resistance. Fast track designation is available for drugs in significant combinations for serious or life-threatening conditions. SEC. 3. CODEVELOPMENT TASK FORCE. Establishment of an interagency task force by the Secretary of Health and Human Services within 6 months of the Act's enactment to promote codevelopment of drugs in significant combinations. Task force membership includes experts in research and drug development for serious diseases. Duties include recommending a list of significant drug combinations for designation under the Federal Food, Drug, and Cosmetic Act. Public input on the list is required. The task force recommends significant drug combinations for designation under the Federal Food, Drug, and Cosmetic Act. The list will be made publicly available for comments, revised based on feedback, and updated annually. The task force will annually update the list of significant drug combinations and submit a policy report to the Secretary and Congress identifying challenges and opportunities for drug codevelopment, along with recommendations for policy changes. The task force will provide recommendations to the Secretary and Congress on policy changes to support the codevelopment of drugs in significant combinations. Before submitting the report, a draft will be made public for comments. The duration of the task force is exempt from the Federal Advisory Committee Act. A significant drug combination is defined as a combination of 2 or more drugs. The task force will provide recommendations on policy changes to support the codevelopment of significant drug combinations. A significant drug combination is defined as a combination of 2 or more drugs that offer potential advancements in treating serious diseases and meet specific criteria outlined by the FDA. The Secretary of Health and Human Services will conduct a study on the impact of exclusivity extensions on significant drug combinations. Interim findings will be shared with a task force and the public for comments, with final findings to be submitted to Congress within 5 years."
}